2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
163
Breast Neoplasms
123
Lung Neoplasms
102
Carcinoma, Non-Small-Cell Lung
84
Glioblastoma
77
Brain Neoplasms
75
Neoplasm Metastasis
68
Glioma
68
Pancreatic Neoplasms
51
Neoplasms
45
Carcinoma, Renal Cell
45
Multiple Myeloma
44
Colorectal Neoplasms
44
Squamous Cell Carcinoma of Head and Neck
39
Lymphoma, Large B-Cell, Diffuse
39
Carcinoma, Hepatocellular
36
Melanoma
35
Ovarian Neoplasms
34
Lymphoma
34
Urinary Bladder Neoplasms
33
Astrocytoma
30
Sarcoma
26
Rectal Neoplasms
26
Uterine Cervical Neoplasms
24
Oropharyngeal Neoplasms
24
Lymphoma, Follicular
24
Central Nervous System Neoplasms
24
Lymphoma, Non-Hodgkin
23
Triple Negative Breast Neoplasms
22
Gliosarcoma
22
Interventions
siltuximab
4
tocilizumab
3
fludarabine
3
Cyclophosphamide
3
fludarabine phosphate
2
Interleukin 1 Receptor Antagonist Protein
2
AP 1903 reagent
2
talquetamab
1
otelixizumab
1
obinutuzumab
1
lopinavir-ritonavir drug combination
1
glofitamab
1
axicabtagene ciloleucel
1
Piperacillin, Tazobactam Drug Combination
1
Oxygen Inhalation Therapy
1
Oxaliplatin
1
Neuropsychological Tests
1
Metoprolol
1
Methylprednisolone
1
Magnetic Resonance Spectroscopy
1
Lopinavir
1
Leukapheresis
1
Infliximab
1
Hydroxychloroquine
1
Heparin, Low-Molecular-Weight
1
Gemcitabine
1
Gelsolin
1
Etanercept
1
Dexamethasone
1
Contrast Media
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cytokine Release Syndrome
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT05510596
2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA
Completed
25 enrolled